Cross-Organ Human Fibroblast Atlas Reveals Unique Roles of Different Myofibroblast Subtypes in Immune Regulation Research Background and Motivation Fibroblasts play critical roles in maintaining tissue homeostasis, inflammatory responses, fibrosis, and cancer progression. In recent years, the diversity of fibroblasts in the tumor microenvironment (...
Fibrotic Response Induced by Anti-CSF-1R Treatment Promotes Glioblastoma Recurrence Background Introduction Glioblastoma (GBM) is a highly aggressive and malignant primary tumor of the central nervous system. Although current standard treatments include surgical resection, Temozolomide chemotherapy, and fractionated radiotherapy, the median surviva...
Fusobacterium nucleatum Promotes Anti-PD-1 Therapy in Microsatellite-Stable Colorectal Cancer Background Introduction With the rise of immune checkpoint blockade (ICB) therapy, a new dawn has emerged in cancer treatment. However, despite the approval of PD-1 targeting drugs (e.g., Pembrolizumab) for certain types of colorectal cancer (CRC) patients...
Background and Research Motivation Esophageal Squamous Cell Carcinoma (ESCC) is a highly aggressive cancer, especially in locally advanced stages. Traditional neoadjuvant chemoradiotherapy (NCRT) is the standard treatment method for this type of cancer. Despite its significant therapeutic effects, local recurrence and distant metastasis rates remai...
Role of Combined Anti-PD-1 and Anti-CTLA-4 Therapy in Melanoma Immune Response Background Immune checkpoint inhibitors have made significant progress in clinical oncology, especially anti-PD-1 (anti-programmed death protein 1) and anti-CTLA-4 (anti-cytotoxic T-lymphocyte-associated antigen 4) therapies, which have been proven to induce long-term re...
Exploration of a Chemotherapy and PD-1 Inhibitor Personalized Stratification Strategy Based on Circulating Tumor DNA in Advanced Non-Small Cell Lung Cancer Background and Significance of the Study Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related deaths globally. In the treatment of advanced NSCLC, the combination of immune ...
Clinical Outcomes and Biological Characteristics Study Report for Pancreatic Cancer Patients with KRAS Mutations Research Background and Objective Pancreatic Ductal Adenocarcinoma (PDAC) is predicted to become the second leading cause of cancer death by 2030. Only about 20% of PDAC patients are eligible for resection surgery, thus the five-year sur...
Background and Research Objectives High-Grade Glioma (HGG) is a highly lethal primary brain tumor with a particularly high incidence and mortality rate in children and adolescents. HGG can be further divided into several subtypes, among which Diffuse Hemispheric Glioma, H3G34-mutant (DHG-H3G34), is a rare subtype with poor prognosis, mainly occurri...
Background Glioblastoma (GBM) is a highly aggressive central nervous system malignancy with very poor prognosis, typically associated with short patient survival. Although significant advancements have been made in tumor treatment technologies and strategies in recent years, traditional radiotherapy and chemotherapy still struggle to achieve satisf...
The Role of Neoadjuvant Chemoradiotherapy Combined or Not Combined with PD-1 Antibody Sintilimab in pMMR Locally Advanced Rectal Cancer: Results of a Randomized Clinical Trial Background and Significance The management of rectal cancer and organ preservation has always been quite challenging, especially in cases of locally advanced rectal cancer (L...